Related Experiment Videos
Intravenous sodium valproate in status epilepticus
1Department of Neurology, Sanjay Gandhi PGIMS, Lucknow, India. sjha@sgpgi.ac.in
Neurology India
|December 4, 2003
Summary
Intravenous sodium valproate effectively controlled seizures in 10 of 11 patients with refractory status epilepticus. This treatment is recommended for myoclonic and non-convulsive status epilepticus, showing no observed complications.
Area of Science:
- Neurology
- Clinical Pharmacology
Background:
- Status epilepticus is a neurological emergency often requiring prompt and effective treatment.
- Patients with refractory status epilepticus may not respond to conventional antiepileptic drugs.
Purpose of the Study:
- To evaluate the efficacy and safety of intravenous sodium valproate in patients with status epilepticus resistant to standard therapies.
Main Methods:
- A cohort of eleven patients with refractory status epilepticus received treatment with intravenous sodium valproate.
- Treatment outcomes, including seizure control and adverse events, were monitored.
Main Results:
- Seizure control was achieved in 10 out of 11 patients within 24-48 hours of initiating treatment.
- No significant complications were reported during the intravenous sodium valproate therapy.
Conclusions:
- Intravenous sodium valproate demonstrates significant efficacy in managing refractory status epilepticus.
- The study recommends intravenous sodium valproate for treating myoclonic status epilepticus and non-convulsive status epilepticus due to its favorable safety profile.